Manufacturer of Controlled Substances; Notice of Application, 17124-17125 [05-6589]
Download as PDF
<![CDATA[
17124
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
of Diversion Control, Drug Enforcement
Administration that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6592 Filed 4–1–05; 8:45 am]
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6585 Filed 4–1–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Application
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 390),
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in Schedule
II:
Schedule
Dihydrocodeine (9120) .................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Cedarburg Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
VerDate jul<14>2003
15:19 Apr 01, 2005
Jkt 205001
Drug
Drug Enforcement Administration
BILLING CODE 4410–09–P
Drug
(CFR), this is notice that on January 4,
2005, Mallinckrodt Inc., Mallinckrodt &
Second Streets, St. Louis, Missouri
63147, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
Schedules I and II:
Pursuant to 21 CFR 1301.33(a), Title
21 of the Code of Federal Regulations
(CFR), this is notice that on February 7,
2005, Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066, made application by letter to the
Drug Enforcement Administration
(DEA) for registration as a bulk
manufacturer of Methamphetamine
(1105), a basic class of controlled
substance listed in Schedule II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than June 3, 2005.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6586 Filed 4–1–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Tetrahydrocannabinols (7370) .....
Codeine-N-oxide (9053) ...............
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Nicomorphine (9312) ....................
Normorphine (9313) .....................
Norlevorphanol (9634) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylophenidate (1724) ..............
Codeine (9050) .............................
Diprenorphine (9058) ...................
Etorphine HCL (9059) ..................
Dihydrocodeine (9120) .................
Hydromorphone (9150) ................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Levorphanol (9220) ......................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone Intermediate (9254) ...
Metopon (9260) ............................
Dextropropoxyphene (9273) .........
Morphine (9300) ...........................
Thebaine (9333) ...........................
Opium extracts (9610) ..................
Opium fluid extract (9620) ............
Opium tincture (9630) ..................
Opium, powdered (9639) .............
Opium, granulated (9640) ............
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
Schedule
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances for
internal use and for distribution to its
customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
E:\FR\FM\04APN1.SGM
04APN1
Federal Register / Vol. 70, No. 63 / Monday, April 4, 2005 / Notices
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than June 3, 2005.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6589 Filed 4–1–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in Schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on January
4, 2005, Mallinckrodt Inc., Mallinckrodt
& Second Streets, St. Louis, Missouri
63147, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in Schedule II:
Phenylacetone (8501) ..................
Coca Leaves (9040) .....................
Raw Opium (9600) .......................
Opium poppy (9650) ....................
Concentrate of Poppy Straw
(9670).
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
II
II
II
II
II
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 392),
Noramco Inc., 1440 Olympic Drive,
Athens, Georgia 30601, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Dihydrocodeine (9120), a basic class of
controlled substance listed in Schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Noramco Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Noramco Inc. to ensure that the
company’s registration is consistent
with the public interest. The
The company plans to import the
listed controlled substances for the
manufacture of controlled substances in
bulk for distribution to its customers.
Any manufacturer who is presently,
or is applying to be, registered with DEA
to manufacture such basic classes of
controlled substances may file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
20:15 Apr 01, 2005
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6591 Filed 4–1–05; 8:45 am]
Schedule
Drug
VerDate jul<14>2003
Enforcement Administration,
Washington, D.C. 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 4, 2005.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in Schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Jkt 205001
PO 00000
Frm 00076
Fmt 4703
Sfmt 4703
17125
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–6584 Filed 4–1–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated December 21, 2004,
and published in the Federal Register
on January 4, 2005, (70 FR 393), Organix
Inc., 240 Salem Street, Woburn,
Massachusetts 01801, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of Codeine (9041),
a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture
small quantities of the listed controlled
substance for use in drug abuse
detection kits.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Organix Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Organix
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR
1301.33(a), the above named company is
granted registration as a bulk
manufacturer of the basic classes of
controlled substances listed.
E:\FR\FM\04APN1.SGM
04APN1
]]>Agencies
[Federal Register Volume 70, Number 63 (Monday, April 4, 2005)]
[Notices]
[Pages 17124-17125]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-6589]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on January 4, 2005, Mallinckrodt
Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)............... I
Codeine-N-oxide (9053)..................... I
Dihydromorphine (9145)..................... I
Difenoxin (9168)........................... I
Heroin (9200).............................. I
Morphine-N-oxide (9307).................... I
Nicomorphine (9312)........................ I
Normorphine (9313)......................... I
Norlevorphanol (9634)...................... I
Amphetamine (1100)......................... II
Methamphetamine (1105)..................... II
Methylophenidate (1724).................... II
Codeine (9050)............................. II
Diprenorphine (9058)....................... II
Etorphine HCL (9059)....................... II
Dihydrocodeine (9120)...................... II
Hydromorphone (9150)....................... II
Oxycodone (9143)........................... II
Diphenoxylate (9170)....................... II
Benzoylecgonine (9180)..................... II
Hydrocodone (9193)......................... II
Levorphanol (9220)......................... II
Meperidine (9230).......................... II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Metopon (9260)............................. II
Dextropropoxyphene (9273).................. II
Morphine (9300)............................ II
Thebaine (9333)............................ II
Opium extracts (9610)...................... II
Opium fluid extract (9620)................. II
Opium tincture (9630)...................... II
Opium, powdered (9639)..................... II
Opium, granulated (9640)................... II
Levo-alphacetylmethadol (9648)............. II
Oxymorphone (9652)......................... II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
for internal use and for distribution to its customers.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
may be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative, Liaison and Policy Section (ODL); or any being sent via
express mail should be sent to
[[Page 17125]]
DEA Headquarters, Attention: DEA Federal Register Representative/ODL,
2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be
filed no later than June 3, 2005.
Dated: March 25, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-6589 Filed 4-1-05; 8:45 am]
BILLING CODE 4410-09-P
